Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited has announced a strategic investment by Lantheus Holdings, totaling up to A$18 million, with an initial A$7.5 million equity investment at a premium share price. This deal includes an option for Lantheus to double their investment and rights to two of Radiopharm’s preclinical assets for an additional A$3 million. The funds from Lantheus will support Radiopharm’s drug manufacturing, clinical trials, and general corporate activities.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
